Qube Research & Technologies Ltd
Position in FULC — Fulcrum Therapeutics, Inc.
CIK 1729829
LONDON, X0
Position in FULC
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$7,476,248
+$3,037,198 QoQ
Shares Held
974,739
+148.3% QoQ
Ownership
1.46%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#24
of 168 holders
Holding Since
Jun 2022
7 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in FULC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Qube Research & Technologies Ltd holds $2,033,804,065 across 186 Biotechnology names. FULC ranks #64 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
838,187 | $277,330,932 | |
| 2 | FOLD |
AMICUS THERAPEUTICS, INC.
|
8,809,340 | $127,383,056 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
3,450,904 | $95,590,040 | |
| 4 | RPRX |
Royalty Pharma plc
|
1,524,511 | $73,130,792 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
83,358 | $64,405,725 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
335,334 | $56,678,152 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
553,290 | $53,807,452 | |
| 8 | CYTK |
Cytokinetics Inc
|
779,446 | $51,373,285 |
All Filings in FULC
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7,476,248 | 974,739 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $4,439,050 | 392,489 | Shares | Sole | 2026-02-17 | |
| 2024-06-30 | $3,430,502 | 553,307 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $6,826,658 | 723,163 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $1,639,629 | 242,908 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | $58,013 | 13,066 | Shares | Sole | 2023-11-13 | |
| 2022-06-30 | $155,883 | 31,813 | Shares | Sole | 2022-08-15 | |
| No filing history on record for this holder in this stock. | ||||||